CD274 and myelodysplastic syndrome: Two randomized phase II trials investigating azacitidine with or without durvalumab (anti‐PD‐L1) as first‐line therapy for older, frail patients with higher‐risk MDS (<20% blasts) or AML (≥20% blasts) demonstrated that the addition of durvalumab did not improve ORR (61.9% vs. 47.6% for MDS, 31.3% vs. 35.4% for AML) or OS (11.6 vs. 16.7 months for MDS, 13.0 vs. 14.4 months for AML) compared to single agent azacitidine treatment.116, 117